3/17
03:48 am
rdy
India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]
Low
Report
India's Zydus, Lupin sign deal to co-market Semaglutide injections [Yahoo! Finance]
3/16
12:25 pm
rdy
Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]
Low
Report
Strait of Hormuz standoff puts supply of America's generic drug prescriptions at risk [MSNBC.com]
3/16
09:39 am
rdy
India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]
Low
Report
India Semaglutide Patent Expiry Could Drive 50% Price Drop in Weight-Loss Drugs [Yahoo! Finance]
3/16
08:32 am
rdy
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]
Low
Report
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results [Yahoo! Finance]
3/16
08:04 am
rdy
Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider [Yahoo! Finance]
Low
Report
Ticagrelor Market Size to Reach USD 3.60 Billion by 2035, Fueled by Rising Cardiovascular Disease Burden and Growing Adoption of Advanced Antiplatelet Therapies – SNS Insider [Yahoo! Finance]
3/16
07:21 am
rdy
Prolonged Strait of Hormuz standoff will close in on America's generic drug prescriptions [CNBC]
Low
Report
Prolonged Strait of Hormuz standoff will close in on America's generic drug prescriptions [CNBC]
3/5
10:04 am
rdy
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's [Yahoo! Finance]
Low
Report
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's [Yahoo! Finance]
2/25
09:52 am
rdy
Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
Low
Report
Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
2/20
10:57 am
rdy
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Low
Report
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
2/17
08:03 am
rdy
Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]
Low
Report
Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]
2/15
06:32 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
2/1
06:31 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
1/30
08:51 am
rdy
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
Low
Report
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
1/25
08:31 pm
rdy
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Low
Report
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
1/21
11:41 pm
rdy
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
Low
Report
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
1/21
04:27 pm
rdy
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
1/21
12:41 pm
rdy
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
1/17
04:31 pm
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
1/14
08:49 am
rdy
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Low
Report
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.